Literature DB >> 1000516

Deveopment of resistance to combinations of six antimetabolites in mice with L1210 leukemia.

F A Schmid, D J Hutchison, G M Otter, C C Stock.   

Abstract

The development of resistance to combinations of 6-mercaptopurine, 6-thioguanine, 6-methylmercaptopurine riboside, methotrexate, 5-fluorouracil, and cytosine arabinoside was studied in L1210 leukemia through 60 transfer generations. The treatment schedules were either simultaneous or offset. In simultaneous administration, one sixth of the LD10 of each of the six drugs was administered within a few minutes, daily for 6 days. In offset administration, the drugs were given either in the above-listed order or in reversed order, with one drug given each day. In the simultaneous combination treatment protocol 31 transfer generations were necessary to reach partial resistance, but in the two offset combination schedules only five and three generations were needed. The relative rate of development of resistance to the individual drugs was slower in the three combination schedules than in single-drug schedules. Resistance to 6-mercaptopurine and 6-thioguanine was completed after four generations on the offset combination schedules, but only after 28 generations on the simultaneous schedule.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 1000516

Source DB:  PubMed          Journal:  Cancer Treat Rep        ISSN: 0361-5960


  4 in total

1.  On mathematical modeling of critical variables in cancer treatment (goals: better understanding of the past and better planning in the future).

Authors:  H E Skipper
Journal:  Bull Math Biol       Date:  1986       Impact factor: 1.758

2.  Evaluation of p-F-Phe-m-bis-(2-chloroethyl)amino-L-Phe-Met-ethoxy HCl against transplantable and spontaneous murine neoplasia.

Authors:  M J Yagi; J G Bekesi
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

3.  Recovery of humoral and cellular immunity by soluble mediators after 5-fluorouracil-induced immunosuppression.

Authors:  V J Merluzzi; K Last-Barney; B M Susskind; R B Faanes
Journal:  Clin Exp Immunol       Date:  1982-11       Impact factor: 4.330

4.  Decreased host toxicity in vivo during chronic treatment with 5-flourouracil.

Authors:  J W Darnowski; R C Sawyer; R L Stolfi; D S Martin; C A Lau-Cam
Journal:  Cancer Chemother Pharmacol       Date:  1985       Impact factor: 3.333

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.